Technology News and Research

RSS

Elective endovascular aneurysm repair benefits men more than women

A study published in the April issue of Journal of Vascular Surgery reports that women derive less benefit than men from elective endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAA's). The research was done at The Vascular Group, The Institute for Vascular Health and Disease, Albany Medical College, The Center for Vascular Awareness Inc., in Albany, NY.

31 Mar 2012

Cambridge Heart fourth quarter total revenue decreases to $557,000

Cambridge Heart, Inc., a developer of non-invasive diagnostic tests for cardiac disease, today reported results for its fourth quarter and full year ended December 31, 2011. Full financial statements and corresponding commentary can be found in the Company's Form 10-K, which will be filed with the Securities and Exchange Commission on March 30, 2012.

31 Mar 2012

CSL Behring initiates rVIIa-FP Phase I study in hemophilia A and B

CSL Behring announced today the first in human dosing of recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP). The Phase I study will investigate in healthy volunteers the safety and pharmacokinetics of rVIIa-FP in comparison to placebo.

31 Mar 2012

Accuray, University of Heidelberg enter multi-year master research and collaboration agreement

Accuray Incorporated, the premier radiation oncology company, announced today the signing of a multi-year master research and collaboration agreement with the University of Heidelberg, a luminary research institution located in Heidelberg, Germany that contributes to the city's top international position in therapy, research and science.

31 Mar 2012

Abbott receives CE Marking for PLEX-ID instrument and assays

Abbott announced today it has obtained CE Marking (Conformite Europeene) in the European Union to market its rapid, high-throughput PLEX-ID instrument, along with three assays for use on the system: PLEX-ID Viral IC Spectrum, PLEX-ID BAC Spectrum BC and PLEX-ID Flu.

31 Mar 2012

Mirada Medical, BioClinica partner to extend oncology clinical trials

BioClinica, Inc., a global provider of clinical trial management solutions, today announced a partnership with Mirada Medical, a leading provider of medical image analysis software. BioClinica will integrate Mirada's XD3 software solution into its imaging core lab technology to further enhance its PET capabilities and expertise for molecular imaging trials.

From Clario 31 Mar 2012

HIT raises $2.75 M USD in Series A funding

HIT Application Solutions, a leading healthcare technology development company, announced today the company has raised $2.75 M USD in its Series A funding effort.

31 Mar 2012

Intronix launches Myoguide Needle EMG Guided Injection System

Great things come in small packages, or at least that's what leading neurologists, physiatrists and clinicians are now discovering with the revolutionary Myoguide Needle EMG Guided Injection System. The breakthrough technology, which has just received 510(k) clearance from the United States Food and Drug Administration, gives practitioners a superior way to deliver targeted injections for musculoskeletal pain, spasticity, fibromyalgia, and even cosmetics.

31 Mar 2012

Blood levels of PCBs in polar bear cubs appear to have dropped

It's never been easy to be a polar bear. They may have to go months without eating. Their preferred food, seal, requires enormous luck and patience to catch. Add to that the melting of Arctic sea ice due to climate change, and the poisoning of the Arctic by toxic chemicals, and it's easy to see why polar bears worldwide are in trouble.

30 Mar 2012

Needle-free vaccine shows promise against RSV in children

Researchers at the University of Saskatchewan are closing in on a needle-free vaccine for respiratory syncytial virus (RSV), a major cause of respiratory illness in children under two years of age.

30 Mar 2012

Cancer cells grow and proliferate more robustly when exposed to human cells

New research from the Technion-Israel Institute of Technology Rappaport Faculty of Medicine and Research Institute and the Rambam Medical Center may lead to the development of new methods for controlling the growth of cancer, and perhaps lead to treatments that will transform cancer from a lethal disease to a chronic, manageable one, similar to AIDS.

30 Mar 2012

Study looks at how health care providers react to medication alerts in EMR systems

A study by Regenstrief Institute and U.S. Department of Veterans Affairs investigators provides the first in-depth look at how health care providers react to medication alerts generated by electronic medical record systems. The researchers plan to use this information to improve the design of medication alerts and diminish the phenomenon known as alert fatigue, where providers can become desensitized and may start unintentionally ignoring some important warnings.

30 Mar 2012

The Lancet acknowledges world's first bedside genetic test

Developed in Canada and conducted by researchers from the University of Ottawa Heart Institute, in partnership with Spartan Bioscience, the world's first bedside genetic test has received acknowledgment by The Lancet, the world's leading general medical journal.

30 Mar 2012

Small electrical sensors can quickly detect MRSA infection

A simple test to identify MRSA in wounds could identify the superbug quickly and help prevent infection from spreading.

30 Mar 2012

Cyberplasm could pinpoint diseases within the human body

A tiny prototype robot that functions like a living creature is being developed which one day could be safely used to pinpoint diseases within the human body.

30 Mar 2012

Viewpoints: IPAB should be 'embraced'; World Bank nominee 'exactly what the doctor ordered'

Controlling costs will require a devilish balancing act among practitioners who resist change, consumer demand and best practices, and IPAB should experiment before imposing radical changes systemwide. But given the devastating, and growing, effects of Medicare spending on the federal debt, the U.S. can't afford not to have an IPAB. The board should be embraced, not feared.

30 Mar 2012

Positive results from Genentech's T-DM1 Phase III trial on HER2-positive mBC

ImmunoGen, Inc., a biotechnology company that develops anticancer products using its Targeted Antibody Payload (TAP) technology, today announced that Roche has announced positive topline results from its trastuzumab emtansine (T-DM1) EMILIA Phase III trial.

30 Mar 2012

Thermo Fisher introduces new HyPerforma S.U.B. TK system

Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Thermo Scientific HyPerforma Single-Use Bioreactor TK (S.U.B. TK), an integrated system that combines the company's proven single-use bioreactor technology with a robust controller platform that enhances functionality and greatly reduces setup times before each production run.

From Thermo Fisher Scientific Inc. 30 Mar 2012

Massively parallel sequencing quickly identifies breast cancer risk gene

An international team of researchers led by the University of Melbourne has used new technology to fast track the discovery of a breast cancer risk gene and could assist in the discovery of other cancer genes.

30 Mar 2012

Study explains how rapamycin also causes insulin resistance

A Penn- and MIT-led team explained how rapamycin, a drug that extends mouse lifespan, also causes insulin resistance. The researchers showed in an animal model that they could, in principle, separate the effects, which depend on inhibiting two protein complexes, mTORC1 and mTORC2, respectively.

30 Mar 2012